Findings show successful prednisolone discontinuation in rheumatoid arthritis patients after bridging therapy, highlighting effective management.
In newly diagnosed patients with RA using bridging therapy when starting methotrexate, over 80% successfully discontinued prednisolone. This supports that tapering to discontinuation is achievable in most patients after short-term bridging with prednisolone, in line with current European Alliance of Associations for Rheumatology recommendations.
No takes yet. Share an insight, caveat, or question.
Brinkmann et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: